CEFAZOLIN — Class II drug recall D-0278-2023
Terminated recall by Sentara Infusion Services, reported 2023-02-22, distributed nationwide. Lack of sterility assurance
| Recall number | D-0278-2023 |
|---|---|
| Product type | Drug |
| Classification | Class II |
| Status | Terminated |
| Voluntary or mandated | Voluntary |
| Recalling firm | Sentara Infusion Services, Chesapeake, VA, United States |
| Recall initiated | 2022-12-27 |
| Classified | 2023-02-15 |
| Reported by FDA | 2023-02-22 |
| Terminated | 2026-02-20 |
| Distributed | Nationwide (US) |
| Reason classes | sterility |
Product
CEFAZOLIN (a) 12GM IN NS 600ML, (b) 2GM IN NS 100ML, (c) 2GM/20ML SW SYRINGE, (d) 3GM IN NS 150ML, antibiotic, used with a curlin, home or no pump assigned. Sentara Home Infusion Pharmacy Services, 535 Independence Pkwy, Ste 300, Chesapeake, VA 23320
Reason for recall
Lack of sterility assurance
Machine access
This record, with every extracted code, the verbatim FDA record and provenance, is available from the recall API: GET https://api.data.aroqon.com/v1/recalls/D-0278-2023. Look up any UPC, UDI, NDC or lot with /v1/recalls/lookup?code=…. API docs · free and paid keys.
Source: U.S. Food and Drug Administration enforcement report via openFDA (CC0). Structured by Data Foundry (recall-structuring@2); last changed 2026-09-26. Not affiliated with or endorsed by FDA. Not medical or legal advice.